Dr. Mulye and Nostrum, a drugmaker located in Missouri and New Jersey, admitted to increasing the price of an urinary tract infection drug more than 400% after changing amounts of two inactive pharmaceutical ingredients, the Justice Department said Oct. 30.
The tweaked recipe was marketed as a “reformulation” and the price of the drug, nitrofurantoin oral suspension, increased from $474.75 to $2,392.32 per bottle in 2018. This “triggered significantly higher Medicaid Drug Rebate invoices from State Medicaid programs,” and Nostrum and Dr. Mulye did not pay the entire invoiced amounts, the Justice Department said.
There was not a legal decision on liability because the case was settled.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
